CoChat
Sign Up
Cited by 91Neuroendocrine regulation and behaviorAutism Spectrum Disorder ResearchGenetics and Neurodevelopmental Disorders

Beyond the hype and hope: critical considerations for intranasal oxytocin research in autism spectrum disorder

Open access
Alvares, Gail A., Quintana, Daniel S., Whitehouse, Andrew J.O.·2017·Autism Research
DOI 10.1002/aur.1692
Open this paper in CoChat — free accountOpen PDF

Abstract

Extensive research efforts in the last decade have been expended into understanding whether intranasal oxytocin may be an effective therapeutic in treating social communication impairments in individuals with autism spectrum disorder (ASD). After much hyped early findings, subsequent clinical trials of longer‐term administration have yielded more conservative and mixed evidence. However, it is still unclear at this stage whether these more disappointing findings reflect a true null effect or are mitigated by methodological differences masking true effects. In this review, we comprehensively evaluate the rationale for oxytocin as a therapeutic, evaluating evidence from randomized controlled trials, case reports, and open‐label studies of oxytocin administration in individuals with ASD. The evidence to date, including reviews of preregistered trials, suggests a number of critical considerations for the design and interpretation of research in this area. These include considering the choice of ASD outcome measures, dosing and nasal spray device issues, and participant selection. Despite these limitations in the field to date, there remains significant potential for oxytocin to ameliorate aspects of the persistent and debilitating social impairments in individuals with ASD. Given the considerable media hype around new treatments for ASD, as well as the needs of eager families, there is an urgent need for researchers to prioritise considering such factors when conducting well‐designed and controlled studies to further advance this field. Autism Res 2017, 10: 25–41. © 2016 International Society for Autism Research, Wiley Periodicals, Inc.

AI snapshot

Written from the paper’s full text.

TL;DR

This critical review argues that intranasal oxytocin research in autism spectrum disorder (ASD) has moved from early hype to more mixed, conservative clinical evidence, with many longer-term trials failing to show significant primary-outcome benefits. It identifies outcome measurement, dosing, delivery device, and participant selection as critical issues for future well-controlled studies.

Key findings

  • Across published work, the review reports 15 randomised placebo-controlled trials, one case report, and two open-label investigations in ASD; single-dose studies suggest acute effects on social cognition, eye gaze, and neural activation, but repeated-administration trials have generally yielded mixed or null primary outcomes.
  • A November 2015 search of five clinical trial registries for “oxytocin” AND “autism” found 57 registered trials; after exclusions, 46 remained, of which 20 were completed and only 65% (n=13) could be linked to publications or registrations, with a conversion lag of about three years.
  • The review states that only 390 individuals with ASD had been reported across 21 publications, with very little investigation in females and almost all studies recruiting higher-functioning individuals.
  • Critical methodological concerns include expectancy/placebo effects, outcome measures not designed for short-term subtle change, no established dose-response study, variability in intranasal device/deposition, and underrepresentation of females and individuals with broader symptom severity.

Methods

  • Design: critical/narrative review of the theoretical rationale and published clinical research on intranasal oxytocin in ASD, including randomised controlled trials, case reports, and open-label studies.
  • Data/sample: the review summarises 15 randomised placebo-controlled trials, one case report, and two open-label investigations in ASD, presented in tables of single-dose and repeated-administration studies.
  • Main analysis: narrative synthesis of clinical, cognitive, behavioural, physiological, and neuroimaging outcomes, plus a registry search of five clinical trial registries in November 2015 for “oxytocin” AND “autism” with no date restrictions; no meta-analytic pooling is reported.

Limitations

  • The paper states that only a small number of individuals with ASD have been studied (390 across 21 publications), with very little investigation in females and almost all studies exclusively recruiting higher-functioning individuals.
  • The paper notes broader field limitations including statistical power, potential publication bias and post hoc analyses, and incomplete understanding of pharmacokinetics; it also states that objective biomarkers have not yet been shown to reliably index oxytocin-related change or correlate with behavioural outcomes.
  • Evident from the text: this is a critical review rather than a systematic review or meta-analysis, and the registry search is limited to five registries and a November 2015 snapshot.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1002/aur.1692

Cites

122 of 122 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

0 of 45 cited sources checked · 0 supported · 0 flagged

  • Findingown data

    Based on the registry search, the conversion from pre-registration to a completed published outcome exhibits a lag of about three years.

    “Based on this search, the conversion from pre-registration to a completed published outcome exhibits a lag of about three years.”
    Quote in the paperNot a substantial claim
  • Findingown data

    Amongst the publications presented in Tables 1 and 2, only 3-7% of reported individuals were female.

    “Amongst the publications presented in Tables 1 and 2, only 3-7% of reported individuals were female.”
    Quote in the paperSubstantial claim
  • Findingown data

    Very little investigation of oxytocin in females with ASD has been conducted.

    “with very little investigation in females”
    Quote in the paperSubstantial claim
  • Findingnone given

    A total of 390 individuals with ASD across 21 publications have been reported being administered oxytocin or placebo.

    “Only a small number of individuals with ASD have actually been reported being administered oxytocin or placebo (a total of 390 individuals with ASD across 21 publications, ranging from randomised trials to open-label investigations and case-studies)”
    Quote in the paperSubstantial claim
  • Findingnone given

    Almost all studies of oxytocin in ASD have exclusively recruited higher-functioning individuals.

    “and almost all studies exclusively recruiting higher-functioning individuals.”
    Quote in the paperSubstantial claim
  • May combine two claims. 23
  • The quote only partly states this claim. 3
  • Classified as probably not a substantial claim. 5

  • May combine two claims. The quote only partly states this claim.

    Findingown data

    A search of five clinical trial registries in November 2015 for oxytocin AND autism revealed 57 registered trials, of which 46 remained after exclusions, 20 were completed, and only 65% (n=13) of completed trials could be linked to publications or retrospectively associated with a registration.

    “Searches for the words”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingnone given

    To date, there have been 15 randomised placebo-controlled trials, one case report, and two open-label investigations of oxytocin in individuals with ASD.

    “To date, there have been 15 randomised placebo-controlled trials, one case report, and two open-label investigations reporting on a variety of different clinical, cognitive, behavioural and physiological outcomes in individuals with ASD ranging from single-dose challenge studies (see Table 1) to various reports of repeated daily administrations (Table 2).”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingnone given

    Most oxytocin studies to date have employed a dose of 24 International Units (IU) in healthy adults, with variable doses employed for children and for repeated administration designs.

    “Most studies to date have employed a dose of 24 International Units (IU) in healthy adults, with variables doses employed for children and for repeated administration designs.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationcitation

    Variable efficacy at the clinical trial end, combined with modest effect sizes in healthy populations, and failed replications, has tempered enthusiasm about oxytocin's potential for reducing ASD symptomatology.

    “However, variable efficacy at the clinical trial end, combined with modest effect sizes in healthy populations, and failed replications, has tempered enthusiasm about the potential of this hormone for reducing ASD symptomatology.4”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [4] source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Several studies have reported lower oxytocin levels in ASD, while others have not exhibited any differences, and one report of increased oxytocin levels in ASD.

    “Several studies have reported lower oxytocin levels in ASD, [17][18][19] while others have not exhibited any differences, 20,21 and one report of increased oxytocin levels in ASD.22”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites [17] source

      Not checked in the free run.

    • cites [20] source

      Not checked in the free run.

    • cites [22] source

      Not checked in the free run.

  • May combine two claims.

    Interpretationcitation

    Some studies employ a dilution method or do not follow manufacturer-recommended extraction of plasma samples before oxytocin assay, which may result in physiologically implausible levels of oxytocin, rendering conclusions about differences between groups, or associations with clinical measures, unverifiable.

    “For example, some studies employ a dilution method 24 or do not follow manufacturer-recommended extraction of plasma samples 25 before oxytocin assay.This may result in physiologically implausible levels of oxytocin, rendering conclusions about differences between groups, or associations with clinical measures, unverifiable.”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [24]

      Not checked in the free run.

    • cites [25] source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    There is considerable debate regarding whether peripheral levels of oxytocin reflect central expression in humans, with mixed evidence reported to date.

    “Lastly, there exists considerable debate regarding whether peripheral levels of oxytocin reflect central expression in humans, with mixed evidence reported to date.26,27”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [26] source

      Not checked in the free run.

    • cites [27] source

      Not checked in the free run.

  • May combine two claims.

    Interpretationreasoning

    Despite initial promise from single-dose administration studies, subsequent clinical trials of oxytocin in ASD have overall failed to deliver upon expectations, with many trials finding little evidence of benefit on primary or secondary outcomes, and any benefits observed associated with small effect size or limited clinical benefit.

    “Despite the initial promise from single-dose administration studies, subsequent clinical trials have overall failed to deliver upon these expectations.Many trials have found little evidence to support benefit on primary or secondary outcomes, and any benefits observed are associated with a small effect size or have limited clinical benefit.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    In Fragile X syndrome, oxytocin administered to eight adolescent and adult males significantly increased overall eye gaze during a brief social interaction compared to placebo, and lower doses appeared to show a greater effect than higher doses.

    “Compared to placebo, oxytocin administered to eight adolescent and adult males with FXS significantly increased overall eye gaze during a brief social interaction.59 Interestingly, lower doses of oxytocin in this sample appeared to show a greater effect than the higher administered dose, consistent with a recent study in healthy adults.60”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [59] source

      Not checked in the free run.

    • cites [60] source

      Not checked in the free run.

  • May combine two claims.

    Interpretationreasoning

    Cumulative experimental findings from single-dose studies suggest that the acute effects of oxytocin in individuals with ASD, mostly male adults with average-to-high cognitive functioning, extend to a number of physiological measures of social cognition, particularly in the modulation of eye gaze.

    “These cumulative experimental findings from single-dose studies suggest that the acute effects of oxytocin in individuals with ASD, mostly male adults with average-to-high cognitive functioning, extend to a number of physiological measures of social cognition, particularly in the modulation of eye gaze.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationreasoning

    The ADOS was not originally designed for use in clinical trials as a sensitive or reliable measure of change in individuals with ASD, and increased social reciprocity observed in the Watanabe trial could be confounded by increased familiarity with the task demands or administrator.

    “Although the primary outcome in this trial, the ADOS, has been utilised in some clinical trials to measure change in clinical symptoms (for example, 56 ), this measure was not originally designed for use in clinical trials as a sensitive or reliable measure of change in individuals with ASD.In particular, increased social reciprocity observed in this trial could also be confounded by increased”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationnone given

    There is currently not enough summary evidence to indicate that biological markers reliably index change due to oxytocin administration, nor whether they correlate with behavioural outcomes.

    “Whilst a promising approach, there is currently not enough summary evidence to indicate that these reliably index change due to oxytocin administration, nor whether they correlate with behavioural outcomes.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    Watanabe and colleagues reported significant improvements in diagnostic symptoms after a six-week oxytocin administration period in high-functioning adults with ASD, specifically on the reciprocity subscale of the ADOS, resting-state functional connectivity between the anterior cingulate cortex and dorsomedial prefrontal cortex, and increased fixations to eye regions.

    “Watanabe and colleagues reported the first evidence of significant improvements in diagnostic symptoms after a six-week administration period in highfunctioning adults with ASD.55 In a crossover design, 20 adults with ASD (18 completed) with average-to-high intelligence were assessed on clinical outcomes of ASD severity, as well as experimental and neuroimaging measures previously shown to be”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [55] source

      Not checked in the free run.

  • May combine two claims. The quote only partly states this claim.

    Premisecitation

    In Prader-Willi syndrome, Tauber and colleagues observed significant improvements in trusting behaviours, reductions in sad mood, and less disruptive behaviour in the two days following a single dose of oxytocin in 24 adults, but a second study found no significant changes in developmental or emotional behaviours and an increase in temper outbursts.

    “Tauber and colleagues observed significant improvements in trusting behaviours, reductions in sad mood, and less disruptive behaviour in the two days following a single dose of oxytocin in 24 adults with PWS.61 A second study of PWS tested effects of twice-daily oxytocin administration over a two month period, in a crossover placebo-controlled design in 30 adolescents and adults with PWS, aged”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [61] source

      Not checked in the free run.

    • cites [62] source

      Not checked in the free run.

  • May combine two claims.

    Interpretationreasoning

    The critical design difference of a crossover randomised trial appears to have ameliorated potential placebo effects and resulted in significant improvements in social communicative behaviours in the recent Watanabe and Yatawara studies.

    “Although both of these recent studies recruited modest sample sizes only, the critical design difference of a crossover randomised trials appears to have ameliorated potential placebo effects and resulted in significant improvements in social communicative behaviours.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

    Interpretationnone given

    The logistical difficulties of magnetic resonance imaging in individuals with sensory difficulties bias recruitment towards relatively high functioning individuals with ASD.

    “Furthermore, the logistical difficulties of magnetic resonance imaging in individuals with sensory difficulties bias recruitment towards relatively high functioning individuals with ASD.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationreasoning

    Translation of evidence to appropriately pre-registered randomised placebo-controlled trials in oxytocin research in ASD has been much more limited, particularly in single-dose crossover challenge studies where pre-registration is often not mandated by journals.

    “Despite the number of studies supporting use of intranasal oxytocin in modulating ASD-relevant social behaviours, social cognition, and neuroimaging markers, the translation of evidence to appropriately pre-registered randomised placebocontrolled trials has been much more limited.This appears to be particularly apparent in single dose crossover challenge studies where pre-registration is often not”
    Quote in the paperSubstantial claim

  • May combine two claims. The quote only partly states this claim.

    Premisecitation

    Yatawara and colleagues reported positive effects of oxytocin on social communication in young children with ASD aged 3 to 8 years, with significant improvements in positive social behaviours as measured by caregiver ratings on the Social Responsiveness Scale, and significant order effects.

    “Very recently, Yatawara and colleagues reported positive effects of oxytocin administration on social communication in the first study of very young children with ASD, aged between 3 to 8 years.57 Similar to Watanabe et al., these authors employed a crossover trial, with a five week administration period of either oxytocin or placebo, switched to the alternate drug after a one month washout period”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [57] source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Dadds and colleagues found no significant differential improvements from four consecutive daily doses of oxytocin compared to placebo in male children with ASD, but it remains unclear whether the lack of effect was due to the complicated study design.

    “No significant differential improvements were observed on changes in parent or experimenter reports of symptoms, or on observed behaviours during interactions.However, it remains unclear whether a lack of effect in this study may be due to the complicated study design.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [51] source

      Not checked in the free run.

  • May combine two claims.

    Interpretationreasoning

    A major consideration in neuropsychiatric clinical trials is the overreliance on reported symptom and clinical observational outcomes, which are vulnerable to subjective biases and placebo effects, particularly given the extensive media hype in this field.

    “A major consideration in neuropsychiatric clinical trials is the overreliance on reported symptom and clinical observational outcomes.Parental or caregiver reports of observed symptom improvement, or researcher observations of behaviour, are vulnerable to subjective biases and placebo effects, particularly given the extensive media hype generated in this field of research.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    Another study of adolescent males with ASD observed no significant benefits of oxytocin after an eight-week administration period compared to placebo, but exploratory analyses revealed that parents who believed their child had received oxytocin reported significant improvements irrespective of actual treatment assignment.

    “Another study of adolescent males with ASD observed no significant benefits of oxytocin after an eight week administration period, compared to placebo.54 No changes were observed on primary outcomes of social behaviours and ratings of clinical improvement, or secondary outcomes examining social cognition, repetitive and other ASD-related behaviours.However, exploratory analyses revealed that”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [54] source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Safety outcomes from a modified maximum-tolerated-dose study in ASD confirm the mild to moderate side effects reported in adult studies, but the open-label design limits interpretations about these reports.

    “Safety outcomes have been recently reported from a modified maximum-tolerateddose study in ASD, 70 confirming the mild to moderate side effects reported in adult studies, 71 however the open-label design limits interpretations about these reports.”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [70] source

      Not checked in the free run.

    • cites [71] source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Interpretationcitation

    Oxytocin could enter the central nervous system through intracellular junctions of the olfactory epithelia to mimic endogenous oxytocin release.

    “could enter the central nervous system through intracellular junctions of the olfactory epithelia 76 to mimic endogenous oxytocin release 77”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [76] source

      Not checked in the free run.

    • cites [77] source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Interpretationreasoning

    Oxytocin could indirectly influence behaviour via oxytocin receptors or cross-reactivity at vasopressin receptors activated at high concentrations.

    “or could indirectly influence behaviour via oxytocin receptors or cross-reactivity at vasopressin receptors activated at high concentrations.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation

    Published case studies and anecdotal evidence suggest off-label prescriptions of oxytocin are already a common practice by treating clinicians, despite concerns about pediatric use outside of a clinical trial setting.

    “Both published case studies 67 and anecdotal evidence 68 suggest off-label prescriptions of oxytocin are already a common practice by treating clinicians, despite concerns about pediatric use outside of a clinical trial setting.69”
    Quote in the paperNot a substantial claim0 of 3 sources checked
    • cites [67] source

      Not checked in the free run.

    • cites [68] source

      Not checked in the free run.

    • cites [69] source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

    Interpretationnone given

    Studies that provide greater consideration for individual differences across the spectrum also require larger sample sizes to statistically account for such individual variability within groups.

    “Studies that provide greater consideration for individual differences across the spectrum also require larger sample sizes to statistically account for such individual variability within groups.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S2 (checkable), S3 (load-bearing), S4 (based).

    Interpretationnone given

    Variations in cognitive capacity, verbal ability, and extent of sensory profiles will provide greater insight into treatment responder subgroups based on behavioural or cognitive symptom profiles.

    “However, variations in cognitive capacity, verbal ability, and extent of sensory profiles will provide greater insight into treatment responder subgroups based on behavioural or cognitive symptom profiles.”
    Quote in the paperNot a substantial claim
27 of 27

  • The paper relies on this without support.

    There is a significant lack of progress in identifying and implementing effective treatments that target core social impairments across the broad spectrum of individuals with ASD.

    “Despite conservative population prevalence estimates exceeding 1% in almost all surveyed countries, 1 there remains a significant lack of progress in identifying and implementing effective treatments that target core social impairments across the broad spectrum of individuals.”

  • The paper relies on this without support.

    There is an urgent need to identify effective therapeutics for ASD to mitigate core social communication deficits.

    “Subsequent investigations into the effects of oxytocin in individuals with ASD have progressed rapidly, due in part to the surge of oxytocin-related publications in the last decade, as well as the urgent need to identify effective therapeutics for ASD to mitigate core social communication deficits.”
2 of 2

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Registered-trial status counts total 45, not 46

    Minor

    The reported categories contain 20 completed, 22 recruiting or recently registered, and 3 withdrawn or unknown studies. These sum to 45, leaving one of the stated 46 studies unaccounted for.

    Reported 46 · recomputed 45

  • Dadds treatment duration is given as both five and four days

    Minor

    The outcome-measures discussion calls study 51 a five-day treatment, while the description of that study says it involved four consecutive daily doses.

2 of 2

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Alvares, G. A., Quintana, D. S., & Whitehouse, A. J. O.
Affiliations
  • The Kids Research Institute Australia (AU)
  • Oslo University Hospital (NO)
Corresponding author
Alvares, Gail A.
ORCID
Venue
Autism Research
Publisher
Wiley
Published
2016-09-21
Volume
10
Issue
1
Pages
25-41
ISSN
  • 1939-3792 (ISSN-L)
  • 1939-3806
DOI
10.1002/aur.1692
OpenAlex
W2526107068
Semantic Scholar
841eea25bebf5eed42cc74c3119442dd51284c6a
Cited by
91
References
122
Citations by year
2026: 5 · 2025: 7 · 2024: 5 · 2023: 9 · 2022: 11 · 2021: 18 · 2020: 9 · 2019: 6 · 2018: 8 · 2017: 12 · 2016: 1
FWCI
1.42
Type
journal article
Language
en
Open access
Licence
Locations
  • Autism Research (publishedVersion)
  • PubMed (publishedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
Funders
  • National Health and Medical Research Council (APP1077966)
  • Research Council of Norway (219483)
Topics
  • Social Sciences › Psychology › Social Psychology › Neuroendocrine regulation and behavior
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Keywords
intranasal oxytocin, autism spectrum disorder, social communication deficits, treatment efficacy, clinical trial design, outcome measures, participant selection, media hype
MeSH terms
Autism Spectrum Disorder, Administration, Intranasal, Humans, Oxytocics, Oxytocin, Research, Research Design, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-09.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-09.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review